Boothbay Fund Management’s Mustang Bio MBIO Stock Holding History

Boothbay Fund Management’s Portfolio MBIO Stock Details MBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Hold	–	-$215K	–	786
2018 Q3	–	Hold	–	–	–	641
2018 Q2	–	Hold	–	–	–	540

Other funds holding MBIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Boothbay Fund Management's MBIO Position: Q3 2022 in Review

Boothbay Fund Management sold out of Mustang Bio (MBIO) in Q3 2022, closing a stake of 29 shares — an estimated $13K sold.

Boothbay Fund Management first reported a position in MBIO in Q4 2019 and held it in 11 quarters. The position peaked at $518K in Q3 2020. 67 funds tracked by Wall St. Rank hold MBIO as of Q3 2022.

Boothbay Fund Management reported no remaining Mustang Bio position as of Q3 2022 after selling out during the quarter.
Boothbay Fund Management sold 29 Mustang Bio shares in Q3 2022, an estimated $13K.
Boothbay Fund Management first reported a position in Mustang Bio in Q4 2019 and held it in 11 quarters.
Boothbay Fund Management's Mustang Bio position peaked at $518K in Q3 2020.
67 funds tracked by Wall St. Rank held Mustang Bio as of Q3 2022.

Based on Boothbay Fund Management's 13F filing for Q3 2022, filed 14 Nov 2022.